We have located links that may give you full text access.
Reoperation Rate After Primary Augmentation With Smooth, Textured, High Fill, Cohesive, Round Breast Implants (RANBI-I Study).
Aesthetic Surgery Journal 2018 November 2
Background: Reoperation after primary breast augmentation remains an important clinical issue.
Objective: Evaluate incidence and causes of reoperation in patients who underwent primary augmentation.
Methods: This retrospective, noninterventional study conducted at 16 Canadian sites reviewed medical records and subject-completed questionnaires of women who underwent primary breast augmentation with smooth or textured Natrelle® Inspira® implants containing TruForm 1 or TruForm 2 gel. Subjects were aged ≥22 years, received implants via inframammary fold incision, and had follow-up at 2 to 4 years.
Results: A total of 319 women received Inspira implants (smooth TruForm 2, n=205; textured TruForm 2, n=99; smooth or textured TruForm 1, n=15). At follow-up, 30 women (9.4%) had undergone reoperation, including 19 (9.3%) in the smooth TruForm 2 subgroup and 9 (9.1%) in the textured TruForm 2 subgroup. The mean time to reoperation was 1.2 years; the risk rate for reoperation was 9.9% at 3 years. The most common reasons for reoperation were implant malposition (36.7%), capsular contracture (33.3%), and the patient's request for a change in implant size or style (20.0%). Most women were very or somewhat satisfied with the initial surgery (89.3% overall; 90.7% smooth TruForm 2; 86.9% textured TruForm 2). Thirty-four women (10.7%) reported adverse events, including 20 (9.8%) in the smooth TruForm 2 subgroup and 14 (14.1%) in the textured TruForm 2 subgroup.
Conclusions: This analysis suggests that Natrelle Inspira TruForm 2 implants are safe when used in primary breast augmentation, with low reoperation rates that are consistent with those for other breast implants.
Objective: Evaluate incidence and causes of reoperation in patients who underwent primary augmentation.
Methods: This retrospective, noninterventional study conducted at 16 Canadian sites reviewed medical records and subject-completed questionnaires of women who underwent primary breast augmentation with smooth or textured Natrelle® Inspira® implants containing TruForm 1 or TruForm 2 gel. Subjects were aged ≥22 years, received implants via inframammary fold incision, and had follow-up at 2 to 4 years.
Results: A total of 319 women received Inspira implants (smooth TruForm 2, n=205; textured TruForm 2, n=99; smooth or textured TruForm 1, n=15). At follow-up, 30 women (9.4%) had undergone reoperation, including 19 (9.3%) in the smooth TruForm 2 subgroup and 9 (9.1%) in the textured TruForm 2 subgroup. The mean time to reoperation was 1.2 years; the risk rate for reoperation was 9.9% at 3 years. The most common reasons for reoperation were implant malposition (36.7%), capsular contracture (33.3%), and the patient's request for a change in implant size or style (20.0%). Most women were very or somewhat satisfied with the initial surgery (89.3% overall; 90.7% smooth TruForm 2; 86.9% textured TruForm 2). Thirty-four women (10.7%) reported adverse events, including 20 (9.8%) in the smooth TruForm 2 subgroup and 14 (14.1%) in the textured TruForm 2 subgroup.
Conclusions: This analysis suggests that Natrelle Inspira TruForm 2 implants are safe when used in primary breast augmentation, with low reoperation rates that are consistent with those for other breast implants.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app